Enable Biosciences

Type 1 diabetes is an autoimmune disease that destroys insulin production by pancreatic islet cells. It affects more than 1.25 million Americans, with 40,000 new cases annually; autoantibody markers can appear before symptoms.

Researchers from Lund University and Enable Biosciences announced significant findings from their latest collaborative study, revealing the superior performance of the automated multiplex Antibody Detection by Agglutination-PCR (ADAP) technology over traditional Radiobinding Assays (RBA) in identify

South San Francisco, CA., April 4, 2024 - [Date] —-- Enable Biosciences Inc., a Stanford and UC Berkeley spinout company focusing on early disease detection today announced the appointment of Will Robberts as its new Chief Financial Officer (CFO) and the closing of an undisclosed equity financing.

Enable Biosciences Inc. launched its Kit to Clinics program for type 1 diabetes care, featuring ADAP (Antibody Detection by Agglutination-PCR) technology, which has been evaluated in peer-reviewed and blinded studies.

Enable Biosciences Publishes Study Revealing ADAP Technology's Improved Accuracy in T1D Risk Prediction South San Francisco, CA Enable Biosciences Inc. has shared compelling new data on the performance of its Antibody Detection by Agglutination-PCR (ADAP) technology in accurately predicting the ri

Carolyn is a Stanford chemistry professor and investigator with the Howard Hughes Medical Institute. Carolyn is elected to the Institute of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences.

510 Myrtle Ave Suite 101 South San Francisco CA 94080 info@enablebiosciences.com

The company develops tools for predictive medicine. Spun out of UC Berkeley and Stanford in 2016, it has partnered with Stanford Healthcare, Harvard Medical School, California Department of Public Health, and JDRF, and reports over 150,000 tests performed.

Effective Date: 6/5/2026 Last Updated:6/5/2026